Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

NACompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

August 10, 2016

Study Completion Date

December 11, 2020

Conditions
Hodgkin Lymphoma, Adult
Interventions
DRUG

Brentuximab vedotin

IV, 1.8mg/kg, every 3 weeks for 6 cycles.

DRUG

ABVD

"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.~Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."

Trial Locations (6)

27599

University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill

27607

Rex Cancer Center, Raleigh

28204

Levine Cancer Istitute, Carolinas Health Care system, Charlotte

37240

Vanderbilt University, Nashville

55905

Mayo Clinic, Rochester

91010

City of Hope Comprehensive Cancer Center, Duarte

All Listed Sponsors
collaborator

Seagen Inc.

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01578967 - Induction Chemo w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter